Connect with us

Media & Technology

Psychedelic Edibles & Expansion of CBD Line; the Run on Gourmet Provisions International (OTCMKTS: GMPR)

Published

on

Gourmet Provisions International (OTCMKTS: GMPR) is making a powerful move up the charts after the Company announced it is in final negotiations with a US Psychedelic Edible manufacturer to produce a custom line of Gourmet Vegan Psychedelic Edibles and expansion of their inventory of CBD products. Last year Gourmet Provisions & CBD partner Brewer & Associates Consulting (under the BWell brand) entered the highly competitive market of CBD Edibles with their Gourmet 1150mg CBD Infused Vegan Fruit Wedges & 10mg all natural Honey Sticks.

This is big news for GMPR which owns 5 wholly owned subsidiaries: Jose Madrid Salsa, Pizza Fusion, Unique Tap House, Unique Foods CBD Edibles & PopsyCakes. GMPR also states for the  2020 3rd quarterly financials posted onto the OTC with strong revenues, $233k profit and $360k+ in Notes off the books. The current total shares issued and outstanding for Gourmet Provisions International Corp. (GMPR) is approximately 29.5 million, with 20+ million restricted and 9.5 million in the public float.

Gourmet Provisions International (OTCMKTS: GMPR) brought on Jack Brewer as GMPR’s Brand Ambassador & Brewer Media & Entertainment Group in October of 2017. Brewer Media Group was brought on to help build all aspects of the many Gourmet brands. With a primary focus on the increase of online and retail sales, social media presence and overall content, public persona and awareness, acquire acquisition opportunities and much more. The company has five wholly owned subsidiaries Jose Madrid Salsa, Pizza Fusion, Unique Tap House, Unique Foods CBD Edibles & PopsyCakes and has a Licensing agreement with Christopher Street Products.

The Company has been busy recently developing a partnership with a NY Times Best Selling Author & Popular Comedian to help establish and launch a Gourmet line of food products starting with his own personal line of Pancake Mix & Syrup all under his custom brand (exciting full details coming in a press release soon).

Pizza Fusion Gourmet Provisions International Corp. acquired the multi award winning Pizza Fusion brand, with existing locations in the US & Saudi Arabia, in March, 2019. In 2006, Pizza Fusion changed the pizza industry with its award winning organic, gluten-free delicious healthy pizzas, with a big emphasis on every product and location keeping to the company’s motto ‘Saving the Earth one Pizza at a Time!’. GMPR announced earlier in December the launch of three Gourmet restaurant quality frozen pizzas under the Pizza Fusion brand:

PopsyCakes “The First & Only Cupcake on a Pretzel” debuted their new PopsyBites on Fox News Channel’s popular show “The Five” and the new bite size gourmet treat has been a big hit ever since in retail. The company signed a 50/50 partnership deal with a Pittsburgh based $16 million annual Candy Company that can handle nationwide production and distribution (more details being announced soon).

To Find out the inside Scoop on GMPR Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GMPR

Christopher Street Products sold out 15+ Unique products in HomeGoods, Wine Enthusiasts Magazine rated the Christopher Street Cabernet Sauvignon an outstanding 90, added distribution through Winelife Distributors NYC. Gourmet Provisions is partnering with a world-renowned cosmetic manufacturer to produce an exclusive line of high-end lipstick (exciting full details in a press release soon).

Jose Madrid Salsa “The Healthy Fundraiser” has continued to dominate in the fundraising category, expanded its Ohio offices & production facility, recently purchased a custom delivery vehicle and will be expanding into many retail outlets throughout the US & Canada (shareholders will be given more updates on this food brand soon).

On December 28 GMPR announced they are in the final negotiations with a US Psychedelic Edible manufacturer to produce a custom line of Gourmet Vegan Psychedelic Edibles and expansion of their inventory of CBD products. Last year Gourmet Provisions & CBD partner Brewer & Associates Consulting (under the BWell brand) entered the highly competitive market of CBD Edibles with their Gourmet 1150mg CBD Infused Vegan Fruit Wedges & 10mg all natural Honey Sticks.

Gourmet Provisions & BWell teamed up a year ago bringing numerous Gourmet high end certified CBD-Infused food products to market and will now expand their current inventory. Gourmet Provision International Corp (on their own) will launch into the new and exciting Psychedelic Edible arena.

James Vowler President & CEO of Gourmet Provisions International Corp. stated, “The opportunity to expand our current line of Gourmet CBD Edible and enter into the exciting ‘fairly new’ world of psychedelic edibles, with all of the health benefits they deliver, is an undeniable win for our company. We have developed a strategic marketing strategy which we believe will be highly successful in building brand recognition, product awareness and most of all sales.”

For more on GMPR Subscribe Right Now!

GMPR is making a powerful move up the charts after the Company announced it is in final negotiations with a US Psychedelic Edible manufacturer to produce a custom line of Gourmet Vegan Psychedelic Edibles and expansion of their inventory of CBD products. Last year Gourmet Provisions & CBD partner Brewer & Associates Consulting (under the BWell brand) entered the highly competitive market of CBD Edibles with their Gourmet 1150mg CBD Infused Vegan Fruit Wedges & 10mg all natural Honey Sticks. This is big news for GMPR which owns 5 wholly owned subsidiaries: Jose Madrid Salsa, Pizza Fusion, Unique Tap House, Unique Foods CBD Edibles & PopsyCakes. GMPR also states for the  2020 3rd quarterly financials posted onto the OTC with strong revenues, $233k profit and $360k+ in Notes off the books. The current total shares issued and outstanding for Gourmet Provisions International Corp. (GMPR) is approximately 29.5 million, with 20+ million restricted and 9.5 million in the public float. We will be updating on GMPR when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GMPR.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GMPR either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.